Arima Genomics Closes Series B Financing to Support Growing Portfolio of 3D Genomics Solutions for Biomedical Research and Translational Applications
Arima Genomics, Inc. has successfully closed a $7 million Series B Preferred Stock financing round, with participation from both new and existing investors, including Genetron Health and Agilent Technologies. The funds aim to accelerate innovation and expand the company’s capabilities in 3D genomics, which provides crucial insights into the structure of genomes, enhancing research and therapeutic development. Arima's technologies are increasingly recognized in precision oncology, with over 600 global customers and more than 200 peer-reviewed studies leveraging its products.
- Closed $7 million Series B Preferred Stock financing round.
- Funds will accelerate innovation and expand product portfolio.
- 3D genomics technology increasingly recognized in precision oncology applications.
- Over 600 global customers utilizing Arima's technologies.
- More than 200 peer-reviewed studies published using Arima's technology.
- None.
Arima Genomics’ technologies provide three-dimensional information about the genome. While most DNA sequencing methods provide linearized DNA data, those approaches do not capture critical DNA structural information. By connecting DNA sequence and structural data, Arima Genomics’ technologies can reveal new biological insights that are indispensable in a diverse set of applications, including helping researchers understand disease mechanisms needed to develop and optimize therapeutic approaches such as cell- and gene-based therapies.
“The increased adoption of 3D genomics indicates the value the life science community sees in understanding the physical organization of genes and how that organization works to drive function and disease,” said
“We see great promise in Arima Genomics’ 3D genomic technologies, especially in emerging precision oncology applications,” said
The funds will support an acceleration of innovation to expand the company’s product portfolio and bioinformatics capabilities to serve a broader spectrum of scientific and translational medicine applications. The funds will also be used to scale the organization to enhance operational and commercial capacity worldwide.
“The body of evidence surrounding the importance of genome structure in health and disease continues to grow – after all, unlike sequence, the structure is highly dynamic both spatially and temporally. Customers have leveraged our technology and published more than 200 peer-reviewed studies advancing the understanding of cancer, neurobiology, immunology, and other complex diseases,” said
About Arima Genomics
View source version on businesswire.com: https://www.businesswire.com/news/home/20220315005371/en/
For media
858.245.5684
gwen@gwengordonpr.com
For general inquiries
415.802.3421
pamela@arimagenomics.com
Source:
FAQ
What is the significance of Arima Genomics' $7 million funding round on GTH,A?
How will the Series B funding help Arima Genomics?
Why is 3D genomics important for GTH,A investors?
What role do existing investors play in Arima Genomics’ financing round?